SCHEMBL24006292

SCHEMBL24006292

N#Cc1ccc2nccc(Nc3cccc(-c4nc5ccc(Nc6ccncc6)cc5o4)c3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 3/20 0.47
▸ GAK O14976 1/20 0.44
▸ RIPK2 O43353 1/20 0.44
▸ COQ8A Q8NI60 1/20 0.44
▸ NLK Q9UBE8 1/20 0.44
▸ RAF1 P04049 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ USP2 O75604 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ CEPT1 Q9Y6K0 1/20 0.38
▸ ALK Q9UM73 1/20 0.38
▸ ABCG2 Q9UNQ0 2/20 0.38
▸ NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24003896 1.00 MAPKAPK2 (0.47) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL25821785 0.95 MAPKAPK2 (0.48) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24006295 0.94 MAPKAPK2 (0.46) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24003893 0.94 MAPKAPK2 (0.46) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999452 0.93 MAPKAPK2 (0.53) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999469 0.93 MAPKAPK2 (0.53) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24006289 0.90 MAPKAPK2 (0.42) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL25821786 0.88 MAPKAPK2 (0.48) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24003901 0.86 KDR (0.44) MAPKAPK2GAKUSP2HPGDCCNC
SCHEMBL24006252 0.86 KDR (0.44) MAPKAPK2GAKUSP2HPGDCCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 — — US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 — — US disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226458-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2021226477-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA MAPKAPK2 136/4885GAK 493/4885RIPK2 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback